Strata Critical Medical, Inc. logo SRTA - Strata Critical Medical, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 6
HOLD 0
SELL 0
STRONG
SELL
0
| PRICE TARGET: $7.25 DETAILS
HIGH: $7.25
LOW: $7.25
MEDIAN: $7.25
CONSENSUS: $7.25
UPSIDE: 35.14%

Stock News

Strata Acquires Heart and Lung Transplant National Recovery Program, Expanding National Organ Recovery Platform

Strata Acquires Heart and Lung Transplant National Recovery Program, Expanding National Organ Recovery Platform

Network of experienced transplant surgeons in key markets will immediately become available to all Strata customers Adds significant scale to Transplant Clinical, Strata's fastest growing business line, with a similar, rapid growth trajectory $21.5 million acquisition completed at mid-single-digit multiple of Adjusted EBITDA, pre-synergy, consistent with Strata's capital deployment strategy NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that it has completed the acquisition of Heart and Lung Transplant National Recovery Program (“HLT-NRP”), a provider of transplant surgical recovery services in the United States. “HLT-NRP strengthens our organ recovery platform by significantly increasing our network of experienced transplant surgeons available to complete recoveries across the country adding clinical depth and geographic reach in key markets such as Florida and California,” said Will Heyburn, Co-CEO of Strata.

Jun 24, 2026 05:00 AM globenewswire.com
Strata Acquires Louisville Perfusion Services

Strata Acquires Louisville Perfusion Services

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that it has completed the acquisition of Louisville Perfusion Services, Inc. (“LPS”), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. “The acquisition of Louisville Perfusion Services fits perfectly with our existing customer base in Kentucky and Ohio, giving us a new strategic stronghold in the Midwest and Southern United States,” said Lou Verdetto, CEO of Strata's Clinical Division.

Jun 02, 2026 05:00 AM globenewswire.com
AIAI Holdings Corporation Announces Appointment of Board of Directors

AIAI Holdings Corporation Announces Appointment of Board of Directors

Directors bring a strong combination of technology, healthcare, national security, leadership experience, and financial and capital markets backgrounds AIAI Expected to Begin Trading on May 14, 2026   DALLAS, TX / ACCESS Newswire / May 12, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI to enhance portfolio performance, today announced the appointment of the Company's Board of Directors. John P. Rochon leads the 10-person Board as Chairman.

May 12, 2026 06:04 AM accessnewswire.com
Strata Critical Medical Announces First Quarter 2026 Results

Strata Critical Medical Announces First Quarter 2026 Results

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the first quarter ended March 31, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only. The results of the divested Passenger business have been reclassified as discontinued operations in all periods.

May 06, 2026 03:00 AM globenewswire.com
Strata Acquires Ohio Valley Perfusion Associates

Strata Acquires Ohio Valley Perfusion Associates

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced that it has completed the acquisition of Ohio Valley Perfusion Associates ("OVPA"), a regional provider of perfusion services to cardiac surgery programs in Ohio and Pennsylvania. “Expanding our presence in Eastern Ohio and Western Pennsylvania is an important step in strengthening Strata's regional clinical platform,” said Louis Verdetto, CEO of Strata's Clinical Services Division.

Apr 30, 2026 12:05 PM globenewswire.com
Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth

Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth

Strata Critical Medical is rated 'Buy' with a 12–24 month horizon, targeting 30–35% upside as valuation remains attractive despite a recent rally. SRTA's transformation into a pure-play medical logistics provider, robust FY25 results, and margin expansion underpin confidence in forward guidance. Industry tailwinds, regulatory catalysts, and an aggressive acquisition strategy position SRTA for sustained revenue and EBITDA growth, with FY26 guidance implying an 11.6% EBITDA margin.

Mar 17, 2026 07:59 PM seekingalpha.com
Strata Critical Medical Announces Fourth Quarter 2025 Results

Strata Critical Medical Announces Fourth Quarter 2025 Results

Revenue increased 83.5% year-over-year to $66.8 million in Q4 2025 Logistics revenue and gross profit grew 35.3% and 39.5% year-over-year, respectively, in Q4 2025, which represents Strata's organic growth Full year 2025 net loss from continuing operations was $20.1 million Full year 2025 revenue and Adjusted EBITDA (1) of $197.1 million and $14.1 million, respectively, both beat the high end of our guidance range Raising full year 2026 revenue guidance to between $260 and $275 million and Adjusted EBITDA guidance to between $29 and $33 million (2) NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the fourth quarter ended December 31, 2025. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.

Mar 03, 2026 02:00 AM globenewswire.com
Strata Critical Medical Schedules Fourth Quarter 2025 Earnings Conference Call

Strata Critical Medical Schedules Fourth Quarter 2025 Earnings Conference Call

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the fourth quarter ended December 31, 2025 on Tuesday, March 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and will include a question-and-answer session for call participants.

Feb 10, 2026 11:00 AM globenewswire.com
Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution

Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution

$30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to $50 million, subject to certain conditions Owned aircraft excluded from collateral package and remain unencumbered NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), a leading provider of logistics and medical services in the organ transplant industry, today announced that the Company has entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans in aggregate principal amount of up to $30.0 million, which, subject to certain conditions, may be increased up to an aggregate of $50.0 million (the “ABL Facility”).

Feb 05, 2026 03:30 AM globenewswire.com
Strata Critical Medical: Likely Valuation Re-Rating After Q4 Earnings (Upgrade)

Strata Critical Medical: Likely Valuation Re-Rating After Q4 Earnings (Upgrade)

Strata Critical Medical, Inc. is refocused on organ transplant logistics after divesting its air passenger business, positioning for higher-margin, long-term growth. SRTA's acquisition of Keystone Perfusion fills a key service gap, boosting market share to 13% and enabling full-stack, technology-agnostic offerings in organ preservation. Keystone's strong FCF conversion (80%) and rapid revenue growth (45% YoY) are expected to drive SRTA's margin expansion and profitability from 2026 onward.

Jan 29, 2026 03:46 AM seekingalpha.com

Price Targets